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Thoughts and emotions are the two functions of the brain that define us as a 
species and define us as individuals. Schizophrenia affects both, and is 
therefore the most human of all diseases. 
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1. Background  
Within the framework of the “Finnmark and Troms Psychosis Project” during the mid-
nineties a group of clinicians worked together to coordinate their clinical work and to 
exchange experiences in the field of early psychosis (1). We also tried to conduct a study of 
incidence of schizophrenia in the two counties Finnmark and Troms, using the Structured 
Clinical Interview for DSM Disorders, SCID (2). This turned out to be more difficult than 
expected – some of it due to the huge geographical area of 26 000 km2 to be investigated, 
and some of it due to extensive discussions on the use of structured diagnostic tools in such 
an early phase of psychosis. During these years there was considerable ideological 
discussion on the topic of diagnoses and stigma among psychiatrists in Tromsø, probably 
more so than in the rest of Norway.  
The incidence study was never completed, but preliminary results showed a much higher 
incidence in males than in females. At this time there was a growing assumption in the 
literature (3-5) that the incidence of schizophrenia in men was higher than in women, after 
a long period of assumed similar incidence rates (6-8). There was also a growing 
understanding of possible gender differences in symptomatology, illness course and 
outcome.  As basic knowledge on how a diagnosis is used is an important prerequisite for 
interpreting epidemiological findings, we wanted to describe more closely the diagnostic 
process, with possible gender differences, before conductance of further epidemiological 
studies. Our hypothesis was that there was more clinical uncertainty involved in assigning 
the schizophrenia diagnosis to women than to men, and we wanted to use the case register 
for admissions to the two psychiatric departments at The University Hospital of North 
Norway to conduct the analyses.  
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The results from the first study (Paper I) inspired us to conduct an experimental study to 
determine whether patient gender as such affected diagnostic practice (Paper II).  Two 
studies on mortality had also been performed, using regular reports on mortality of patients 
with mental illness in Norway (9-12) since 1916, and the same case register at the University 
Hospital with follow-up 1980-1992 (13-14). These studies documented an increase in 
standardized mortality ratios (SMRs) compared to earlier periods, especially high for men.  
With the studies on gender differences in diagnostic practice as baseline knowledge, we 
decided to conduct a 27-years follow-up study by investigating the difference in age-
adjusted mortality rates between men and women with schizophrenia, and SMRs compared 
to the general population (paper III).  
2. List of papers 
1. Høye A, Hansen V, Olstad R (2000) First-admission schizophrenic patients in northern 
Norway, 1980-95: Sex differences in diagnostic practice. Nord J Psychiatry 54: 319-325 
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3. Introduction 
Schizophrenia is a syndrome characterized by a complex symptomatology, affecting most 
aspects of cognition, emotion and behaviour. After more than 100 years of research and 
inquiry there is still a lack of an integrative explanation for the diversity of signs, symptoms, 
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course and treatment of schizophrenia, even though the attempts have been many within 
different theoretical frameworks. The classification of schizophrenia highlights an important 
conflict of modern psychiatry – namely; how to link the clinical relevance of a concept to its 
validity and reliability. The development and background of the diagnosis and concept of 
schizophrenia is therefore of relevance to all research within the area, and it is therefore 
essential to present some of the general history and theoretical background in this chapter. 
3.1 Schizophrenia - the diagnosis 
Before the nineteenth century references to insanity mostly occurred in “all-or-none” 
terms; with description of pure signs, leaving little room for subjective experience 
(symptoms). This has been described in the book “The History of Mental Symptoms” by GE 
Berrios (15). Throughout the nineteenth century, however, there were several attempts 
made to classify the historical, nonspecific concept of madness or insanity, influenced also 
by the discussion of the relation between thought and language. Early descriptions of 
“thought disorders” rely on the assumption that language and thought are not the same 
thing, exemplified by the French physician Jean-Etienne Dominique Esquirol (1772-1840) 
who already in 1838 distinguished between nonsense talk secondary to abnormal 
sensations (hallucinations) and primary pathology of the “faculty that is in charge of 
coordinating ideas”. As outlined by Berrios, the development of descriptive pathology within 
the area of psychiatry can be looked at on the basis of six historical factors: 1) the 
descriptive needs of the new asylum officers, and the new patient cohorts, 2) the availability 
of psychological theories that might support stable descriptions, 3) the changing notions of 
signs and symptoms in medicine in general, 4) the introduction of subjective 
symptomatology, 5) the use of time as a contextual dimension and 6) the development of 
quantification. The creation of descriptive psychopathology started around the second 
decade of the nineteenth century, it represented a major shift in the perception of insanity 
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and it took about 100 years to complete. The changes since then have been quite small, 
revisions and refining of the categories taken into consideration. 
The term psychosis was introduced by the physician Karl Friedrich Canstatt (1807 -1850) in 
1841, and used from the second half of the century in the German-speaking countries (16). 
The term was understood as a cerebral pathology expressed by psychic symptomatology, 
with a differentiation of the categories of endogenous and exogenous psychoses made by 
the neurologist Paul Julius Möbius (1853-1907). Emil Kraepelin (1856-1926), professor of 
psychiatry in Heidelberg and Munich, introduced a differentiation of Möbius’ terms by 
introducing a new conceptual framework making a distinction between dementia praecox 
and manic depressive insanity (17, 18). Kraepelin described dementia praecox as a brain 
disease characterized by a downward course to a state of chronic impairment, featuring 
neurological abnormalities, physical anomalies and deterioration of the intellect. Many of 
Kraepelins “psychic symptoms” were considered by him as manifestations of thought 
disorders (17, 19). His ideas were supported and introduced in France, where his 
categorization had encountered much opposition, by the French psychiatrists Paul Sérieux 
(1864-1947). The term schizophrenia (from Greek: schizen - “to split” and phren – originally 
“diaphragm” but later changing, by metonomy, to “soul, spirit, mind”) was first used by the 
Swiss psychiatrist Eugene Bleuler (1857 – 1939) at a meeting of the German Psychiatric 
Association in Berlin on April 24, 1908 (20): 
 “For the sake of further discussion I wish to emphasize that in Kraepelin’s dementia praecox 
it is neither a question of an essential dementia nor of a necessary precociousness. For this 
reason, and because from the expression dementia praecox one cannot form further 
adjectives nor substantives, I am taking the liberty of employing the word schizophrenia for 
revising the Kraepelinian concept. In my opinion the breaking up or splitting of psychic 
functioning is an excellent symptom of the whole group".  
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Bleuler collected material directly from his clinical work, and his theory of “schizophrenia” 
linked Kraepelin’s neuropathological description to Freud’s psychoanalytic concepts and 
terms, with the help of psychologist Gustav Jung (1875-1961). Bleuler realized that 
schizophrenia was not a single disease (Bleuler E. 1911: Dementia praecox or the group of 
schizophrenias. Translated by Zinkin J. New York, International University Press 1950), and 
he considered the splitting of different psychological functions, resulting in a loss of unity of 
the personality, to be the most important sign of the disease. He described the 
pathognomonic symptoms to be thought disorder, affective disturbance, autism and 
ambivalence, but considered hallucinations and delusions to be symptoms of lesser 
importance. Neither Kraepelin nor Bleuler used the terms “positive” or “negative“ 
symptoms, this was a distinction first mentioned by John Hughlings Jackson (1835 -1911) to 
try to explain the mechanisms underlying psychotic symptoms. Jackson’s attempt to make 
distinctions between different sets of symptoms was influenced by Darwinian evolutionary 
theories of the brain being organized in different hierarchical evolutionary layers.  
Albeit a somewhat different view on symptomatology and importance of different 
symptoms to describe the syndrome, both Kraepelin, Bleuler, Jackson and others during the 
same period tried to understand symptoms in terms of underlying neurological mechanisms 
specific of the syndrome, and to understand the interplay between neurological and 
psychological mechanisms. Their findings encouraged the need to formulate operational 
rules for defining schizophrenia, to specify whether or not a patient will be placed within a 
particular definition of schizophrenia according to the presence or absence of a given set of 
features.   
Throughout most of the twentieth century Bleuler’s perspective with “the four A’s” 
(Associations, Affect, Ambivalence and Autism) dominated the nosology of schizophrenia 
(20). This emphasis did, however, change during the 1960’s and 1970’s. Influenced by the 
 9 
work of the phenomenologist Karl Jaspers (1883-1969), the German psychiatrist Kurt 
Schneider (1887-1967) discussed the importance of form rather than the content of a sign 
or a symptom, and his description of so-called first-rank symptoms had a strong influence 
on the concept of schizophrenia (17). The Schneiderian first-rank symptoms were based on 
easy-to-recognize psychotic symptoms such as hallucinations and delusions, and, as 
described by Nancy C. Andreasen, “satisfied the fundamental need to find an anchor in the 
perplexing flux of the phenomenology of schizophrenia” (17).  Schneiderian symptoms were 
included into the first major structured interview Present State Examination (21), and 
thereafter in structured interviews and diagnostic criteria as seen in the Diagnostic and 
Statistical Manual (DSM-III) from 1980. 
3.2 Diagnostic reliability, validity and utility 
The history of mental symptoms can be explored through four complementary perspectives 
(15): Descriptive psychopathology, etiological theory, pathogenesis and taxonomy. The 
concept of schizophrenia must be viewed in light of all these dimensions, and throughout 
the last decades there has been an increasing tendency towards reifying taxonomy to 
comprise all four of them. In extension, the development of diagnostic criteria in psychiatry 
has profoundly affected several aspects of clinical practice in both positive and negative 
terms. The standard frame of reference has certainly enabled diagnostic agreement and 
facilitated clinical communication. Research on morbidity, health services, treatment and 
outcomes has been facilitated and refined by the greatly improved diagnostic reliability. 
Diagnostic reliability in this setting means that a diagnosis must be inherently repeatable – 
that is; under the same conditions different clinicians or researchers must be able to 
generate the same diagnostic conclusions.  
The literature on general validity within research is abundant, and a thorough discussion of 
the subject is not within the aims of this thesis. However, it has been increasingly recognized 
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that the fundamental issue of validity of psychiatric diagnoses cannot be solved by explicit 
decision rules and description of diagnostic entities, and some important issues must be 
kept in mind when discussing diagnostic practice in psychiatry.  
The word “valid” is derived from the Latin validus (“strong”), and it is defined as “well 
founded and applicable; sound and to the point; against which no objection can fairly be 
brought” (22). In research, the general use of the word addresses the nature of reality – 
whether or not a concept describes what is “real”.  In 1970, Robins and Guze (23) published 
one of the most influential articles in the development of psychiatric classification. They 
stressed the importance of diagnosis and classification, and suggested an approach for 
validation. The five criteria they proposed have since then been the standard criteria for 
establishing so-called diagnostic validity: clinical description, laboratory studies, 
specification of exclusion criteria, follow-up studies to determine outcome and studies of 
familial aggregation. Since then Andreasen (24, 25) has refined these validation criteria by 
including more recent knowledge within areas potentially capable of linking symptoms and 
diagnoses to etiology; such as neurochemistry, molecular genetics and cognitive 
neuroscience.   
The validation of psychiatric diagnoses is meant to establish them as “real entities” (23), but 
to acquire diagnostic validity as described above it is in fact necessary to accept the implicit 
assumption that the given disease entity “schizophrenia” is “real”  - with a higher or lower 
degree of validity. As research on genetic and neurodevelopmental etiology progresses it 
may very well be that the “real” entity is to be found somewhere else than in a given 
diagnostic description.  
The DSM-system was in many ways developed as a result of the work of Robin and Guze. 
Nevertheless, the originally developed “provisional consensus agreement” of the DSM-
system was based on clinical evaluation by a small group of psychiatrists, and was probably 
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never intended to be used as a full description of mental disorders. The unquestionable 
need for defined disease entities has, unfortunately, hampered an open discussion on the 
shortcomings of the systems both in research and clinical practice – once a disease entity is 
listed and defined in a precise, complex way as in the DSM- and ICD-systems, it tends to be 
reified.  
Even if most contemporary psychiatric disorders (even schizophrenia) cannot yet be 
describes as valid disease categories, they may still be valuable concepts, as stated by 
Kendell and Jablensky (26). They underline, however, the importance of not 
underestimating the distinction between validity and utility. Kendell and Jablensky propose 
that a diagnostic rubric may be said to possess utility “if it provides nontrivial information 
about prognosis and likely treatment outcomes, and/or testable propositions about 
biological and social correlates”. In other words, the utility indicates whether the diagnosis 
is of clinical importance when it comes to outcome prediction or choice of treatment. Utility 
may therefore be a graded characteristic, while validity cannot. There may be uncertainty 
about the validity of a syndrome or diagnosis because crucial empirical knowledge is lacking, 
but a diagnosis cannot be “partly valid”. Diagnostic categories defined by their syndromes 
should, according to Kendell and Jablensky, only be considered valid if they have shown to 
be discrete entities with clear boundaries or qualitative differences that separate them from 
other syndromes at the level of the defining characteristic. They argue against defining 
validity such that no syndrome of unknown etiology could be accepted as a valid category - 
because understanding of etiology is not an all-or-none issue, and because clear boundaries 
may be apparent long before the underlying etiology is known. Schizophrenia, as most other 
psychiatric disorders and many somatic disorders, is a clinical syndrome (or several 
syndromes) with largely unknown etiology, and the issues of reliability, validity and utility 
must therefore be kept in mind. Even so, it is important that a lack of validity (in the strict 
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sense) does not hold us from open-mindedness towards investigating on the basis of the 
existing concepts. It is important to remember that it is research on the basis of the current 
schizophrenia concept that has brought on the new, basic questions on e.g. etiology, and 
that investigating the boundaries of the current syndrome is crucial to obtain new 
knowledge. 
3.3 Schizophrenia diagnosis today 
Schneider’s first-rank-symptoms and the attempt to identify symptoms fundamental for the 
“core” of schizophrenia set the terms for the classification process from the 1960’s (27). 
Schneiderian symptoms were included in the International Pilot Study on Schizophrenia 
(28), the Present State Examination (21), and from then on refined and processed in 
different versions of structured interviews. From the beginning of the seventies two 
different sets of systems evolved – one in USA, and one of more European origin. Newer 
versions of these two different sets of diagnostic criteria are still used throughout the world 
– the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, DSM IV (29) and 
the World Health Organization’s International Classification of Diseases, Tenth Revision, ICD-
10 (30). The DSM-system is used in almost all studies conducted in the US and also in many 
studies that comprise use of biological markers, while the ICD-system is the system clinically 
used in Europe and in many international epidemiological studies.   
Even though there have been continuous efforts by the work groups of the two systems 
during the last decades to achieve as much concordance as possible, there are still 
important differences between the systems that complicate international research. In most 
respects, the DSM has a narrower conceptualization of schizophrenia than the ICD, as a 
consequence of an explicit effort to narrow the concept as it had been used in the US until 
the IPSS-study was conducted. Both DSM and ICD require one month of active symptoms 
and the presence of psychotic symptoms such as delusions and hallucinations, but while 
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DSM requires 6 months of overall duration of symptoms, only one month is required in ICD. 
There are also some differences in subgrouping, e.g., in the DSM schizotypal disorder is 
placed among the personality disorders, while in ICD it is placed under the general heading 
of schizophrenia. 
In Norway, ICD-8 was used up to 1987, when there was a change to ICD-9. According to 
Scandinavian tradition, clinicians had up to then tended to postpone the diagnosis of 
schizophrenia, taking into consideration Langfeldt’s chronicity criteria (31, 32). Even if the 
criteria did not change, an explanatory appendix was included in the ICD-9 version, probably 
to influence Norwegian clinicians to consider giving the schizophrenia diagnosis at an earlier 
point in the disease course to adjust Norwegian practice to international standards. ICD-10 
for mental disorders has been used in Norway from 1997. 
During the last years, there has been an extensive discussion in international research 
literature on the concept of schizophrenia. In some ways, the present meets the past – the 
focus on purely descriptive symptoms is being heavily criticized, and the attempts of 
Kraepelin, Bleuler and others to understand symptoms in terms of their underlying neural 
mechanisms have to some extent had a new renaissance (33). The issues of validity, 
reliability and utility mentioned above have also been of importance when it comes to the 
discussion of the schizophrenia diagnosis. Many researchers argue that the schizophrenia 
concept must be fundamentally changed, and that defining complex psychiatric disorders on 
externally observable phenotypes (such as behaviours) is not at all optimal for getting closer 
to knowledge on etiology, treatment and outcomes (34, 35). 
It is underlined that the current world of schizophrenia most likely include multiple, 
phenotypically overlapping syndromes, and also that it will be essential to think in 
dimensions instead of categories.  
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 Before classification can be meaningful, there must be a conceptualisation of syndromes, as 
outlined by Keshavan MS et al in the article with the descriptive title “Schizophrenia. “Just 
the facts” 6. Moving ahead with the schizophrenia concept: From the elephant to the mouse 
(36):  
“If we are to make real progress in unravelling the nature of the many disorders that are all 
currently called schizophrenia, the field must boldly step outside the schizophrenia box”. 
In some of the current literature there is also a strong link to the attempt of Kraepelin, 
Bleuler and others to describe the clinically distinctive and typical elements of schizophrenia 
– the “something” experienced by clinicians, the fundamental discussion of what 
schizophrenia really “is”. Parnas (27) and others claims that the “core” of schizophrenia is 
inevitably linked to all domains of consciousness and experience of “self”, and that the 
overall change in patients with schizophrenia stretches far through the single symptoms and 
signs. Parnas argues that the existing operational definitions only capture a fragment of this 
clinical core – “The clinical core manifests itself, and is graspable, as a larger whole, a 
Gestalt emerging across a manifold of symptoms and signs” (27).  A phenomenological 
description of these fundamental features of schizophrenia is therefore claimed to be 
crucial, to understand both the etiology and the clinical manifestations of the syndrome.  
 
Due to the uncertainty of diagnosis in an early phase of psychosis, it has also been argued 
that there are only three primary categories with that should be considered, on the basis of 
treatment consequences – psychosis as defined within the group of schizophrenia 
diagnoses, bipolar disorder and depressive disorder with psychotic features (37, 38).  
 
A revision of DSM IV is planned in 2012, and it remains to see to what degree the 
international debate on the schizophrenia concept will be reflected in the revision.  
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3.4 Incidence and mortality 
The incidence of a disease is the rate at which new cases occur in a population during a 
specified period. In the simple situation that the population is relatively constant, incidence 
is measured as the number of new cases/population at risk × time during which the persons 
became ill. For example: the number of new cases of schizophrenia in Norway in 2011/ 5 
million Norwegians. In the more complicated situation when the follow-up differ for 
different subjects and may also be many years, we calculate person-years and estimate the 
incidence rate as the number of new cases during follow-up/total number of person-years 
of follow-up. The word "mortality" is derived from "mortal", which come from the Latin 
"mors" (death). Mortality is the incidence of death. We may calculate e.g., the total (all-
cause) mortality, sex-specific mortality (mortality in men and women separately), age-
specific mortality (e.g., mortality in subjects aged 50-59) or cause-specific mortality (e.g., 
mortality of suicides). 
The standardized mortality ratio (SMR) is a measure of mortality in a study population, 
relative to mortality in a reference population. The SMR answers the following question:  
“How does the number of observed deaths compare with the expected number of deaths, if 
our study group had the age-specific mortality rates of the reference population during 
these study years?”(39). In our study, this means that the SMRs compare the observed 
number of deaths in the group of patients with schizophrenia with the expected number of 
deaths in the same group, as predicted by age- and sex-specific mortality rates in the 
Norwegian population.  This was done by calculating the number of deaths to be expected 
among the patients if the mortality rates of the general population in Norway according to 
age (5-year groups) and calendar year (5-year groups) during follow-up had prevailed. 
SMRs from different countries are difficult to compare, due to large differences in mortality 
in general populations.  Several studies do, however, show a significantly higher risk of 
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premature death in persons with schizophrenia than in the general population (40, 41, 42 -
44). Ösby et al (45) showed a marked increase in all-cause SMR for both men and women 
over a period of 23 years, a trend that was also seen in a meta-analysis by Saha et al (46) 
based on standardized mortality ratios from 25 countries. A meta-analysis by Brown et al, 
on the other hand, showed no increase in all-cause SMR between the 1970s and the 1990s 
(47). Findings on gender differences have also been somewhat equivocal - Brown et al (43) 
found slightly higher all-cause SMR in men, but the difference was not statistically 
significant, while Mortensen and Juel (48) found age-specific SMRs to be higher for women 
than for men.  
3.5 The use of case registers 
The first psychiatric case register in the world was created in Norway by psychiatrist Ørnulf 
Ødegård (1901-1983); the Norwegian Case Register of Serious Mental Disorders (9-12).  He 
regularly documented morbidity and mortality in hospitalized psychiatric patients from 
1916. The register was used in several Norwegian studies, e.g., in linkage with twin registers 
(49 - 51). The quality of the register did, however, gradually decline from the late sixties. The 
use of psychiatric case registers had grown also in several other European countries during 
the sixties and seventies (52), but due to lack of funding, political reasons and excessive 
concerns on privacy issues several of them were closed down in the eighties, including the 
Norwegian register mentioned (closed in 1988). During the last three decades, however, the 
use of psychiatric registers in research has grown, especially in the Scandinavian countries. 
Use of electronic patient records has expanded, and general technological development has 
been extensive. The ability to follow patient populations longitudinally throughout a long 
time span and the possibility to link with other data sources opened new options in 
psychiatric epidemiological research, as well as in health management. Improved 
confidentiality is also important.  
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Psychiatric case registers can be institution-based or population-based. As Tansella states 
(52), institution-based means a systematic collection of data on individuals treated at a 
specific hospital or psychiatric service, while population-based means patient- centred 
longitudinal records of contacts with a defined set of psychiatric services, originated from a 
defined population. In both cases, information is stored in a cumulative file so that each 
patient can be followed over time. Both types of registers can be used for research and 
management purposes, as well as for clinical quality assurance and improvement. 
Nevertheless, as use of psychiatric case registers has grown, the distinction between 
administrative health care registers and case registers for research purposes has faded 
away. Most registers can be used for both administrative purposes as well as for quality 
improvement and research, if one keeps in mind the different legislative regulations linked 
to the actual purpose of data usage and strict rules of confidentiality.  
As the population registers in the Nordic countries were centralized and computerized, the 
personal identification number has been used in all national statistic systems. This person 
number is unique and independent, because it is the sole identifier for one particular 
individual and for that person alone. It is also permanent. Thus, the person number provides 
a personal identifier that enables handling for comparing, sorting and record linkages (53). 
The largest psychiatric case register used for both research and health care management 
can be found in Denmark (The Danish psychiatric case register). Denmark has had a person-
identifiable patient register with national coverage from 1977, as have Finland and Sweden - 
from 1969 and 1987, respectively (54).  Until 2008, there was no nationwide registration in 
Norway of admission to hospitals that included the personal identification number. The 
Norwegian Patient Registry has first and foremost had health administrative purposes, 
including activity based financing. The data have not yet been of satisfactory quality for 
psychiatric research. There are a few Norwegian population-based epidemiological studies 
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containing some measurements on mental health and/or psychiatry (The Tromsø Study, the 
Nord-Trøndelag Health Study (HUNT)) that may be used for linkage with regional case 
registers or research registers. In Denmark, Finland and Sweden the person-identifiable case 
registers have provided data for e.g. a recent study on general life expectancy of patients 
with mental disorders, including comparison between the countries (55). Due to the lack of 
such a register in Norway until 2008 there has been no possibility to follow similar national 
cohorts, but hopefully this will be possible within some years. 
Better register-based research has certainly given an indispensable contribution to 
psychiatric epidemiology and knowledge. Register-based studies are cost-effective in terms 
of collecting data on large samples (54-58) over long time periods, and they make it possible 
to obtain sufficient statistical power in analyses of low-prevalence syndromes such as 
schizophrenia. They also provide gentle research methods, because no actual burden is 
placed on the patient involved – strict privacy issues of course taken into account. According 
to an overview by Mortensen (59) register-based studies can be used in studies of 1) 
prevalence and incidence, 2) treatment course or episodes of care, 3) studies of defined 
patient groups selected from the register and followed separately in other clinical, 
randomized or epidemiological studies, 4) studies of risk factors of mental illness where 
both exposure and outcome data come from the same register and 5) record linkage studies 
combining data from the register with other sources. Much of the knowledge we have about 
the schizophrenia syndrome today is based on register studies – e.g. incidence rates, the 
high mortality compared to the general population and the role of urbanity, migration 
status and obstetric complications as risk factors (60). In the present thesis, a case register 
has also been used to obtain more knowledge on clinicians’ practice and the concept of a 
diagnosis. In addition, the challenge of treatment and outcome measurement in psychiatry 
often makes it difficult to conduct randomized controlled trials within other areas than 
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medication treatment. In a world where randomized controlled trials are considered the 
“gold standard” of evidence-based medicine, this may in fact lead to a kind of “evidence-
based bias”. In any case, analyses from register-based studies are an important means to 
generate hypotheses that can be further explored in randomized controlled trials and 
clinical studies. Well-conducted register studies may therefore give considerable additional 
value to the general area of psychiatric research. They also give us data about the true case 
mix of the patient population as well as the normal treatment of them. This is contrast to 
the often substantially selected group of patients that are included in most randomized 
clinical trials and the more careful treatment and follow-up usually offered them.   
3.6 Sex and gender differences in schizophrenia 
The words sex and gender are commonly used interchangeably, even if their linguistic 
definitions are quite distinct - sex refers by definition to the biological and physiological 
characteristics, while gender refers to behaviours, roles, expectations, and activities in 
society. The reason why the terms are confusing and used interchangeably in the area of 
psychopathology is probably the lack of clear knowledge on presumed etiology, which is 
also the case for differences between men and women. Deaux (61) underlines that a simple 
distinction between “sex” and “gender” without any assumptions about etiology may be a 
more useful approach, and he suggests “sex” for comparisons “..in which people are 
selected on the basis of the demographic categories of male and female” and “gender” for 
comparisons involving “...the nature of femaleness and maleness, of masculinity and 
femininity”. This view was supported by Lewine (62). Still, the correct or at least consistent 
use of the terms is not easy, as can also be seen in this thesis where biological and/or 
cultural differences between men and women (or males and females) are not always easy to 
separate! 
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Recently, there have been several attempts to distil schizophrenia science into a set of facts 
(35, 36), and to distinguish between basic facts, etiological facts, pharmacological and 
treatment facts, pathological facts and behavioural facts. Differences between men and 
women with schizophrenia will inevitably arise from this interplay of sex hormones, 
neurodevelopmental and psychosocial sex and gender differences, and even if there are 
significant differences between men and women in several aspects, the degree of overlap 
seems to be substantial. The findings with regard to differences in men and women with the 
disease are also equivocal when it comes to sex differences in family history, obstetrical 
complications, minor physical anomalies and physical soft signs; it is therefore reason to 
believe that the neurodevelopmental model of schizophrenia accounts for the majority of 
schizophrenia in both sexes. When it comes to etiological facts, there is a complex interplay 
of genes and environmental factors that contributes in development of the schizophrenia 
syndrome, which genetically seems to be a catch-all term for several sub-syndromes. 
According to an update by Center for Human Genome Variation at Duke University (63), 
there may be anywhere between 100 and 10 000 genes with mind-damaging mutations, but 
how they function depends on a person’s other genes and a multiplicity of factors in their 
environment. 
An important theory with considerable support is the hypothesis that estrogen provides 
relative protection to premenopausal women (3, 64 - 66). The effects may be structural or 
functional. Structural effects are due to developmental change before brain maturation, 
extending from the prenatal period to puberty. The female brain shows earlier 
establishment of neuronal connections, lateralization of brain functions and axonal 
myelination (67) compared to the male brain. This relative immaturity of the early male 
brain and slower rate of development may make it more vulnerable to early brain insults, 
resulting in structural brain abnormalities associated with early onset and more negative 
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symptoms. The hypothesis of estrogen having a functional antipsychotic effect by modifying 
neurotransmitter functioning and thereby being a protective agent raising the threshold for 
psychotic symptoms may explain much of the gender differences in disease course (60, 61, 
63). 
3.6.1 Incidence and prevalence 
Kraepelin stated already in 1893 that men were three times more likely than women to 
show the described features of dementia praecox. Despite Kraepelin’s observations there 
was little research focusing on sex differences until the late 1980’s. The annual incidence of 
schizophrenia was reported to be from 5.0 to 20.0 per 100 000 (3) and it was generally 
accepted not to vary according to sex (6, 68).  
During the last decades, the earlier assumptions that schizophrenia is equally distributed in 
different cultures and between males and females have been questioned (4, 67, 69 -71).  A 
meta-analysis based on all publications on incidence of schizophrenia from 1980 -2001 by 
Aleman et al (72) provided evidence for a sex difference in the risk of developing 
schizophrenia, as did the systematic review of 158 studies by McGrath et al (40). In the 
review by McGrath et al the median annual incidence of schizophrenia was found to be 15.2 
per 100 000. The central 80 % of estimates varied over a fivefold range (7.7 – 43.0 per 
100 000), and there was prominent variation between sites. The incidence rates also 
differed significantly between men and women; the median (10, 90 percent percentiles) 
rate ratio for male: female estimates was 1.4 (0.9, 2.4).  
The sex differences in incidence are, however, not reflected in prevalence - the review of 
188 prevalence studies by McGrath et al showed a median lifetime prevalence of 7.2 per 
1000 inhabitants  (3.1, 27.1), with no significant difference between males and females. 
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Neither Saha et al (73), nor a Finnish study from 2007 (74), showed any difference in 
prevalence between men and women.  
The discussion of incidence and prevalence rates in psychiatry invariably comprises the 
application of diagnostic criteria (41), and the estimation of incidence and prevalence has to 
a great extent depended on the diagnostic inclusion criteria used. Lewine (62) demonstrated 
that the stricter the diagnostic criteria, the higher the proportion of men compared to 
women with schizophrenia. This is also stated by Leung and Chue - the broader the inclusion 
criteria, the smaller the difference in incidence between men and women (67). The 
described use of meta-analyses and reviews of different studies may therefore provide the 
most comprehensive knowledge on the incidence and prevalence of schizophrenia. 
3.6.2 Age of onset 
It is a quite robust finding across many studies that men have a 3-5 years earlier age of 
onset of schizophrenia than women. According to the review article by Leung and Chue (67) 
sex difference in age of onset has been shown to exist irrespective of culture, definition of 
onset (first sign of a mental disorder, first psychotic symptom, age of diagnosis, first 
treatment, first hospital admission) or definition of illness (various diagnostic systems 
including different versions of DSM and ICD). Leung and Chue point to the fact that earlier 
age of onset in men does not seem to appear due to differences in health-seeking behaviour 
of the patient or the family, and Faraone et al found sex difference in age of onset to persist 
after correction for sex differences in the age distribution of the population (75). 
The distribution curves for age at onset do not only show a shift towards older age for 
women. Men show a modal incidence in their late teens and early twenties (ages 15-25) and 
perhaps a second, small peak around middle age (65, 67, 76). Women also show modal 
onset in their early ages, but the peak is lower and broader (ages 15 -30) followed by a 
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second, more pronounced peak than men at ages 45-49, and a third peak over the age of 
65. Thus; there seem to be a switch from male predominance in incidence during the early 
twenties to female predominance in incidence in older ages. These distributions seem to be 
in accordance with the estrogen theory mentioned above. According to Leung and Chue (67) 
the age of onset sex difference is more evident in sporadic schizophrenia than in 
schizophrenia with high degree of family loading, as also found by Suvisaari et al (77).  
3.6.3 Symptom presentation and course of illness 
It is by no means evident in what way gender predicts symptomatology and course of illness 
(1,41,54). Häfner (65) argues that there are no gender differences in symptomatology, and 
without consideration of age there are no gender differences in symptom-related course of 
illness. However; Häfner claims that the effect of oestrogen on the level of gene expression 
and transmitter functioning results in higher age of onset and a reduced severity of illness 
until menopause. In an Australian study from 2008, Morgan et al (78) looked at gender 
differences and psychosis across different diagnostic groups, and found that women in all 
diagnostic groups reported better premorbid functioning, a more benign course of illness, 
lower level of disability and better social integration than men. The differences between 
men and women across the diagnostic groups were more obvious than within each group, 
even if women with schizophrenia were more severely disabled than women in the other 
diagnostic groups. 
Even though there is considerable overlap in symptomatology between the sexes, it still 
seems to be substantial evidence that men with schizophrenia display more negative 
symptoms, while women have a higher frequency of affective symptoms. This may be partly 
explained, as stated by Flor-Henry (79), by women being more likely to express affective 
symptoms than men overall, and that the difference is related to general gender differences 
when it comes to affective expressivity. 
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Abel et al (76) and Leung and Chue (67) hold forward that older age of onset and a higher 
degree of affective symptoms generally predict better outcome and are associated with 
female sex in the majority of studies. Early age of onset and negative and disorganized 
symptoms are associated with worse short and medium outcomes, and are also associated 
with male sex. Females therefore seem to have better short-term and middle-term 
outcomes than men, but the differences attenuate in the long term. There is no strong 
evidence that age of onset or sex predict course and outcome independently of symptom 
profile at presentation.  
Overall, findings seem to suggest that the complex picture of hormonal and 
neurodevelopmental sex-specific brain abnormalities in schizophrenia may be largely 
associated with the sex-specific factors contributing to normal brain development. 
Nevertheless, as described by Häfner, the scarcity of knowledge of differences in the 
development, morphology and functioning of the female and male brain do not allow any 
definite conclusions. Sex and gender differences in schizophrenia also reflect sex differences 
in the healthy brain, general cultural gender differences and general social effects when it 
comes to symptomatology and disease course.  As Flor-Henry said already in 1983 (79): “Sex 
differences in symptom expression in schizophrenia may be related to gender differences (in 
illness expression) rather than schizophrenia per se.”  
4. Aims of thesis 
The aims of this thesis were: 
1. To describe the diagnostic process in a cohort of first-admitted patients with 
schizophrenia, with emphasis on gender differences. 
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2. To determine whether gender as such had any influence on diagnostic practice among 
psychiatrists in Norway and in the Arkhangel region in Russia, based on a case 
simulation. 
3. To investigate whether there are difference in age-adjusted mortality or standardized 
mortality ratios (SMR) between men and women with schizophrenia in the counties of 
Troms and Finnmark.  
5. Material and methods 
5.1 Material 
5.1.1 The case register of Psychiatric Division at the University Hospital of North Norway 
(Papers I and III) 
The creation of a case register for all admissions to the Psychiatric Divisions of the hospital 
was initiated by Vidje Hansen in the mid-eighties, as an institution-based, administrative 
register. The original purpose was to use this computerized register to overview patient 
flow, but throughout the last two decades it has been increasingly used for research 
purposes. The register starts with new admissions from 01.01.1980, covering all admissions 
to the two divisions, and includes patients already being in-patients at start. The updating 
for the period 1993 to 1995 was done by the author, and from then on, the updating and 
quality control has been done by Vidje Hansen and Anne Høye in collaboration. At present, 
the register covers the period from 01.01.1980 to 31.12.2006. The University Hospital of 
North Norway is the only psychiatric hospital covering the two northern-most counties in 
Norway; Troms and Finnmark. These counties comprise a vast area of approximately 26 000 
km2, with a total of 224 407 inhabitants in 2000. The register has been continuously checked 
and validated against patient files, and is considered to be complete with no missing values.  
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Paper I is based on first-ever admitted patients with a minimum of three admissions from 
January 1st 1980 to December 31st 1995, the case register being the only data source. Paper 
III is based on the period from January 1st 1980 to December 31st 2006. Some of the analyses 
are performed only on this case register cohort, while others are based on linkage.  
5.1.2 The Norwegian Cause of Death Register (paper III) 
All physicians in Norway are required to complete a death certificate, and all death 
certificates are collected by the Cause of Death Register for coding of information based on 
International Classification of Diseases (ICD) - currently ICD-10. The Section for Health 
Statistics at Statistics Norway is the Data Processor for the Cause of Death Register, and the 
Norwegian Institute of Public Health is the Data Controller. For the period 1951-2010, the 
cause of death data is available in electronic format from Statistics Norway. The data are 
usually released with one year delay. 
Norway has committed itself to classify and report the cause of death statistics in 
accordance with the ICD-classification and rules for coding underlying cause of death. The 
underlying cause of death means 1) the illness or injury that initiated the series of the 
morbid conditions that led directly to death, or 2) the external circumstances of the accident 
or act of violence that caused the fatal injury. Beyond the underlying cause of death, 
complications and contributing factors are coded – up to four in 1969 to 1995 and up to six 
from 1996.  
5.1.3 Data file of psychiatrists’ answers 
A case description was in 2000 sent to all 980 members of the Norwegian Psychiatric 
Association, a specialist branch of the Norwegian Medical Association, and to all 163 
psychiatrists in the Arkhangel area in Russia. A total of 467 psychiatrists answered, 392 from 
Norway and 75 from the Arkhangel region in Russia (40 % and 46 % response rate, 
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respectively). They were asked to participate in a study of diagnostic practice, and to 
suggest a tentative diagnosis on a written case description of a patient in early phase of a 
psychosis. All the analyses in the study described in paper II are based on this data file on 
Norwegian and Russian psychiatrists.  
5.2 Methods 
5.2.1 Use of case-register 
Information used in the analyses was the personal identification number; date of admission; 
commitment status; date of discharge and diagnosis at discharge. Schizophrenia was 
defined according to the International Classification of Diseases (ICD-9: 295, ICD-10: F20, 
F21 and F25). Before 1985, ICD-8 was used, and the diagnoses in this period were converted 
retrospectively to ICD-9 codes. 
In the study presented in paper I, 151 patients (60 women and 91 men) who were admitted 
for the first time during 1980-1995 were included. They had a total of 1326 admissions. By 
restricting the cohort to patients admitted at least three times, we secured repeated 
observations on each patient. 84 first-admission patients were hence excluded. 
One of the analyses performed was to assess the latency period before first schizophrenia 
diagnosis. Diagnoses are formally registered at the day of discharge, the latency period 
therefore being defined as the mean time from first day of the first admission to the last day 
of the admission at which the first schizophrenia diagnosis was given. In addition, analyses 
of diagnostic shifts from first admission until schizophrenia diagnosis was performed, as well 
as analyses on diagnostic stability after schizophrenia diagnosis. This was done by assessing 
how many patients kept their diagnosis unchanged, how many had intermediate diagnoses 
before returning to schizophrenia and how many were re-diagnosed permanently after 
firstly having received schizophrenia diagnosis. 
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In paper III, differences in age-adjusted mortality rates between men and women in the in-
patient cohort were studied. During the study period there were 22 434 admissions. 5840 
persons were admitted, 2724 females and 3116 males. A total of 1111 patients, 38 % of 
them were women, received at some point a schizophrenia diagnosis. One of the 
hypotheses tested was whether the relationship between gender and mortality in the 
cohort persisted during different three follow-up periods with increasing degree of de-
institutionalization. We also looked at differences between patient admitted for the first 
time before or after 1992, to see whether the relationship between gender and mortality 
depended on when the patients had their first admission. The year 1992 was chosen partly 
of analytical reasons (to have enough deaths for a meaningful analysis in the last period), 
partly because a follow-up ending in 1992 has previously been published (13, 14).  
Finally, we wanted to investigate if there were any differences in mortality in relation to use 
of compulsory treatment. According to The Norwegian Act relating to the establishment and 
provision of mental health care (the Mental Health Care Act), compulsory mental health 
care may be provided in an institution approved for this purpose if a given set of criteria is 
fulfilled. We divided the cohort into three groups – those who had always been voluntarily 
admitted, those who had been admitted sometimes voluntarily and sometimes by use of 
compulsory care, and those who had always been committed by use of compulsory care.  
5.2.2 Case simulation study 
The design of the study described in paper II approaches behavioural research, as it is a kind 
of experimental study on physician’s decision-making. We wanted to investigate association 
between patient gender and decision-making among psychiatrists, and to see whether there 
was a systematically biased interpretation by psychiatrists concerning gender and 
schizophrenia diagnosis. Our study questions demanded an experimental design and we 
chose to use a case simulation (a case vignette). On the basis of a discussion among three 
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experienced clinicians, a case description of a 27-year old patient was designed. The patient 
had symptoms that could be interpreted as schizophrenia in an early phase, but with room 
for doubt concerning the diagnosis. The psychiatrists were invited to participate in a study 
of diagnostic practice based on a case description, and they were specifically informed that 
there was no “medically correct” answer as it was a study on diagnostic practice as such. 
The answers were returned anonymously. The psychiatrists were not informed that half of 
them were introduced to the case vignette describing a male patient, the other half a 
female. Apart from the patient being described as “he” or “she” the stories were identical. 
The two gender versions of the vignette were randomly assigned in the male and female 
group of psychiatrists. They were asked to provide information on their own gender, age, 
whether they were specialists or in the process of specialising and main area of interests.   
The hypothesis tested was whether gender of the patient affected diagnostic decision, and 
we also wanted to analyze whether gender of clinician, age, experience and area of interest 
influenced on their diagnostic decision. 
5.2.3 Register linkage 
In paper III, a linkage between the case register of University Hospital of North Norway and 
the Norwegian Cause of Death Register was performed, using the unique personal 
identification number as the identification variable. The personal identification number was 
also used for obtaining information held by Statistics Norway concerning emigration.  
We studied gender differences in SMRs for patients with schizophrenia compared to the 
general Norwegian population, and as described for the in-patient cohort we wanted to test 
whether all-cause SMRs changed over three follow-up periods characterized by increasing 
de-institutionalization, or whether differences were related to first admission before or 
after 1992. We also divided into natural and unnatural causes of death, further sub-
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grouping natural causes into cardiovascular diseases, cancer and others, and unnatural 
causes into suicide and others. We also looked at the importance of commitment status for 
difference in all-cause SMRs.  
5.2.4 Statistical methods 
The statistical methods used in the study are described in the different papers. Means, 
medians and proportions (%) were used to describe cohort characteristics. Chi-square tests, 
independent sample t-tests, Wilcoxon test, simple factorial analysis, multiple regression 
analysis and Cox regression with attained age as the time variable were used to analyse 
gender differences. Age adjustments of the mortality rates and statistical testing of 
differences between mortality rates were carried out by applying a Poisson regression 
model. For comparison with the mortality of the general Norwegian population, indirect age 
adjustment was used, according to age (5-year groups) and calendar year (5-year groups). 
6. Overview of results 
6.1 Paper I 
Women had a significantly longer latency period than men from first admission until the 
first diagnosis of schizophrenia was given, both in total amount of time (2.6 years versus 1.6 
years) and in number of admissions (3.4 versus 2.3 admissions). 33 % of the women 
received the diagnosis at their first admission, as opposed to 47 % of the men. The 
diagnostic pattern before the schizophrenia diagnosis was given was also somewhat 
different – men received to a higher degree reactive psychoses, while women were 
diagnosed with personality disorders. Schizophrenia diagnosis was found to be stable after it 
had been given, with no clear differences between men and women. Diagnostic stability 
was, however, strongly associated with a longer latency period – that is; higher stability 
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reflects a higher degree of diagnostic certainty.  The impact of the shift from ICD-8 to ICD-9 
in 1987 was also investigated, showing that the diagnostic guidelines resulted in shorter 
latency period even if the criteria were not changed. Nevertheless, the gender difference 
persisted. 
6.2 Paper II 
The study showed that a schizophrenia diagnosis was both in Norway and in Russia given 
significantly more often to the male story than to the female story. The differences 
persisted both with and without schizotypal disorder included. In the schizophrenia group of 
diagnoses, the Russians were less likely to put down a diagnosis of schizotypal disorder than 
the Norwegians. Country, gender of clinician, age of clinician and clinician’s main area of 
interest did not affect the results in a logistic regression, where odds ratio for the male case 
versus the female case receiving a schizophrenia diagnosis was 1.8 (1.2-2.8). 
6.3 Paper III 
The 1111 patients were followed for a total of 16 129 person-years. During the total period 
of 27 years there was a stable bed-to-population ratio of approximately 4 per 10 000 
inhabitants.  
192 men and 103 women died during the 27 years period. 2.1 % of the men and 1.9 % of the 
women died during first year of follow-up. In both men and women, 20.4 % of the patients 
with schizophrenia died of natural causes, a similar proportion of them of cancer (4 %) or 
cardiovascular diseases (9 %). A larger proportion of the males (7.6 %) than of the females 
(3.8 %) died of unnatural causes; suicide was the registered cause of death for 5.8 % and 2.1 
% of men and women, respectively. Male patients in the cohort had nearly twice the 
mortality of female patients, the hazard ratio being 1.9 (CI: 1.5, 2.4). 
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The study showed that men and women had 3.5 and 2.6 times higher total mortality than 
the general population, respectively (p =0.01 for the difference between genders). The 
gender differences for each of the examined causes were not statistically significant, but the 
SMRs were higher for men than for women for both natural and unnatural causes of death. 
The SMR for cancer was lower than for all natural causes combined, and was for women not 
significantly different from the cancer mortality in the general population. As expected, very 
high SMRs were found for suicides; the SMR was 17.0 for men and women combined. 
Always voluntarily admitted men had lower all-cause SMR, while the opposite was found in 
women – always voluntarily admitted women had higher all-cause SMR than those who had 
been sometimes or always committed by use of compulsory care. All 16 deaths in this group 
of women had natural causes. 
All-cause SMRs were higher for both men and women during the last nine years than the 
first nine years, and for women admitted for the first time after 1992 there were signs of 
increasing difference in mortality compared to the general female population. The rise was 
particularly high for unnatural causes of death (6.6 versus 16.0), and especially for suicide 
(9.6 versus 50.2). The numbers are, however, very small in this group, and caution must be 
made in interpretation. As a conclusion, however, the SMR for total mortality of women 
with schizophrenia is rising and becoming just as high as for men, both for natural and 
unnatural causes of death.  
7. General discussion - methodology 
7.1 Internal validity and bias 
Internal validity is a description of the degree to which conclusions about causal 
relationships can be made, based on the measures used, research setting and design. 
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External validity concerns to what extent the (internally valid) results can be applied to 
other populations, that is; the generalizability of the results. 
Bias is any kind of systematic error that affects the result in a way that reduces the internal 
validity. Bias may be classified in several categories – most usually selection bias, 
information bias and confounding.  
7.2 Completeness of the case register (papers I and III) 
All information in the computerized register has been checked against patient files. To our 
knowledge, the register is complete – that is; all persons that actually have been admitted 
since 01.01.1980 are included. There are, however, a very small number of missing values in 
some of the variables. In all, the register comprises 6044 persons, of which 5840 had a valid 
personal identification number, and 51 variables. Only in 6 of these variables are there any 
missing values at all, the number of persons with missing values ranging from 0.6 % to 2.9 % 
of the total 6044 persons.  Even so, in a retrospectively validated register there may still be 
missing values, but the errors these may introduce for gender differences in the analyses 
are considered negligible. 
7.3 Diagnostic reliability in the register (papers I and III) 
Diagnoses in the register have been made by clinical judgment and consensus, and not by 
standardized diagnostic procedures. Many psychiatrists have been responsible for 
determining the diagnoses, and this may of course have affected diagnostic reliability. There 
is reason to believe that there has been, especially during the first years of the register, a 
cautious attitude towards diagnosing patients. It is therefore more likely that a person with 
the disease will not get the diagnosis than that the opposite happens, especially during the 
first 15 years. Still, the incidence rate in the age group 15-55 years was 11.1 per 100 000 
inhabitants (8.8 for females and 13.3 for males), which is within the described range of 
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international incidence studies (40). The diagnostic hesitation has changed with time, and 
there has been a clear trend towards coordination with the rest of Norway.  Still, no 
reliability study has ever been made, and this requires caution when it comes to diagnostic 
reliability. 
7.4 Bias in the case register (paper I and III) 
In a study based on case registers selection bias means that the sample studied is not 
representative of the total population of interest. This can affect both the internal and the 
external validity of the studies.  
In a case register based on in-patients only there may be different subcategories of selection 
bias that must be considered (52). Geographical bias applies to whether the register only 
comprises people living in one area, in our register this could be the case if most patients 
admitted to the hospital came from e.g. the city of Tromsø (where the hospital is located) 
and not from rural areas. It is well known that travelling time to care is of importance when 
explaining differences in use of health services (80, 81). It may therefore be that patients 
with long travelling distances (up to 1000 km) or from small, rural communities use the 
psychiatric hospital to a lower degree. It is unclear to what degree this would affect our 
results – some studies have found higher prevalence rates of schizophrenia in cities (82), but 
it must be underlined that Tromsø in this respect is a relatively small city with only 70 000 
inhabitants. Also, the psychiatric health services in Troms and Finnmark are exclusively 
public, and there are well-established cooperation lines from the hospital to the smaller 
treatment units and outpatient clinics. This cooperation was probably less established 
during the first years of the register, that is; there might have been a greater loss due to 
geographical causes during the early years of the register. Still, it is not very likely that this 
possible geographical bias would affect gender differences found in paper I or III. 
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Another form of bias could arise from the fact that in some of the smaller municipalities in 
the two counties there is a majority of Sami inhabitants, and earlier studies on utilization of 
medical services have shown a lower average consultation rate in Sami than in the general 
Norwegian population. In a recent study from the same area by Gaski et al (83), however, 
overall public somatic hospital expenditure in Sami municipalities was above national 
average. Even if this study does not comprise psychiatry, there are no clear indications that 
Sami people are admitted to hospital to a lower degree, and even so there is little reason to 
believe that there has been a gender specific skewness.  
Another aspect of selection bias is treatment bias - in this setting meaning to which degree 
only severe cases are admitted to hospital. For every case register where only in-patients 
are included there is always a risk for exclusion of mild cases, even so in our studies.  
Treatment bias may have affected the results in paper I. It might be that men with extensive 
symptoms is the group most often admitted to hospital, and that women have a longer 
delay before they are finally admitted. Still, the assumption that men are “more ill” at 
admission is countered by the fact that the mean total observation time at first admission is 
not higher for men than for women, and the overall total observation time is significantly 
higher for women than for men. Sub-typing of the schizophrenia diagnosis also gives a hint 
that women must have had serious symptoms also before diagnosis was set (paranoid and 
hebephrenic). A possible treatment bias of women being treated for a longer period outside 
hospital before admission should lead to a shorter latency period. Hence; an attenuation of 
the findings would have been more likely. 
Also when it comes to paper III, treatment bias may have affected these results. If the 
register only contains the most seriously ill patients, and more so as the 
deinstitutionalization developed, it may be that SMR appears to be higher than it would 
have been if all patients with schizophrenia were included. The time trend showing the 
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increased SMRs for the whole group of patients in the second period may therefore be 
biased upward if patients with less symptoms are treated elsewhere than in-hospital. This 
implication does, however, require lower SMRs in patients with less symptoms, a theoretical 
association that has not been investigated in our study. 
Assessing the finding of higher SMRs for women admitted for the first time after 1992, the 
results may be biased if a higher degree of deinstitutionalization leads to a higher 
proportion of relatively well-functioning women never being admitted to the hospital. If 
that is the case, the time trend of higher SMR may be tautological - as time goes by it is the 
more severely ill women that are admitted, leading to higher SMRs than the general female 
population, which again leads us to think that it is the deinstitutionalization that causes the 
enhanced SMRs. Again, this requires an implication of more symptoms leading to higher 
SMR. Still, one of our puzzling findings was the inverse relation between SMR and use of 
coercion for women. This may mean that these relatively well functioning women in fact 
have higher SMRs, which again may indicate that also never-admitted women with 
schizophrenia – to the extent to what they actually exist in the catchment area (the counties 
of Troms and Finnmark) – still may have high SMRs. 
Information bias in a register study is associated with loss to follow-up due to death or 
emigration out of the area, lack of information prior to first entry due to in-migration to the 
area covered, failed linkage and periods of discontinuity in the register (52).  We consider 
the chance of information bias to be relatively low – in paper III, linkage with the national 
Cause of Death Register excludes all loss of follow-up due to migration from Troms and 
Finnmark. Loss of follow-up due to migration from Norway still cannot be excluded, but the 
numbers are low – 6 out of the 1111 patients with schizophrenia (Paper III) emigrated 
during 1980 -2006. The use of the personal identification number excludes bias due to failed 
linkage. There are no discontinuity periods in the register.  
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The case register contains no information on psychiatric symptomatology or other clinical 
correlates such as BMI, blood pressure, smoking, drug abuse or other factors that may affect 
mortality (44, 84 - 87). There may of course be several confounding variables that affect 
results in both paper I and III. The main topic discussed is, however, the gender differences, 
and in order to explain them there must be strong correlations between patient gender and 
possible, unknown confounders. 
7.5 Bias in the Cause of Death Register (paper III) 
All deaths in Norway are usually certified by a physician, on rare occasions the death 
certificate may be signed firstly by the police before being confirmed by a physician. The 
Cause of Death Register is validated against Statistics Norway twice a year, and death 
certificates are also controlled against other existing information (autopsy reports, the 
Norwegian Register of Birth, hospital records when needed, the police road accident 
register etc). “Underlying cause of death” is registered, which means 1) The illness or injury 
that initiated the series of conditions that led directly to death, or 2) The outer 
circumstances of the accident or act of violence that caused the fatal injuries (88). A source 
of uncertainty in the cause of death statistics is, according to Gjertsen (88), partly the cause 
of death investigation and partly physician reporting of information on the death certificate. 
Another potential source of error is the classification, coding and input made by medical 
coders. In practice, classification and coding of underlying cause of death is difficult when 
multiple causes of death have been reported and several sequences are possible, and it can 
develop local code cultures that prefers certain diseases than others. Nordic research on the 
cause of death statistics shows that statistical comparisons can be problematic due to 
differences in coding, medical culture and working practices, although the classification 
used is the same (89). In addition, there is always a risk of underreporting suicides, as there 
may be an overweight of external causes being registered as accidents. Another potential 
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source of bias is the number of persons dying abroad with no registered cause of death. 
Some Norwegian citizens die abroad – i.e. 394 persons in 2008 (90). In 90 % of these cases 
there is no registered cause of death. There is, however, no reason to believe that these 
examples should affect the gender differences shown in paper III. 
 
7.6 Antipsychotics and mortality 
The use of antipsychotic drugs could theoretically be a confounder when it comes to SMR 
combined for both sexes. During the last years there has been a growing concern that the 
well-known side-effects of some of the second-generation antipsychotics (increased BMI, 
increased risk of metabolic syndrome, other possible effect on cardiovascular risk factors) 
may increase the mortality of patients with schizophrenia. In a review by Smith et al (91) 
from 2008, there was tentative evidence that the second-generation antipsychotics included 
in the studies were associated with a small increased risk of diabetes, but the results were 
difficult to interpret. Other studies the last few years possess ambiguity – Bushe et al (92) 
concludes that there is some evidence that long-term exposure to antipsychotics increases 
mortality, but more research is required. This is also the conclusion in a review by 
Weinmann (93). Tiihonen et al (94), on the other hand, found in their large, register-based 
study that long-term treatment with antipsychotic drugs is associated with lower mortality 
compared with no antipsychotic use. Use of clozapine seemed to be associated with a 
substantially lower mortality than any other antipsychotics, mostly due to lower rate of 
suicide, while the heterogeneous group of “other” second-generation antipsychotics 
seemed to be associated with higher all-cause mortality than perphenazine. The 
methodology and findings in this study have been debated (95). The conclusion so far seems 
to be that more research is required, as also stated by Kelly (96).  
In our study, it is of course possible that use of antipsychotic drugs may have contributed in 
some way, but it is less likely that the gender difference as such is affected. 
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7.7 Selection bias among psychiatrists (paper II) 
Norwegian Psychiatric Association had 980 members in 2000, comprising 69 % of all 
Norwegian psychiatrists. Response rate of the study was 40 % in Norway and 46 % in Russia, 
and this quite low response rate taken into consideration there might be a selection bias. 
Bias could in principle affect the results in both directions – the psychiatrist not participating 
could be more or less prone to give a schizophrenia diagnosis given the sex of the patient. 
Gender distribution in the Norwegian sample was found to be representative of all 
Norwegian psychiatrists and that of members of the Norwegian Psychiatric Association. 
Responders were slightly younger (mean age 50.7) than the total population of specialists 
(mean age 54.9) and members of Norwegian Psychiatric Association (mean age 53.0). The 
slightly younger age of the participating clinicians may have resulted from the fact that in 
the total cohort of members there are several who are not longer practicing. Also, it may be 
that younger clinicians were more interested in participating in research projects. It is, 
however, difficult to see how the relatively low response rate or the slightly skewed age 
distribution could bias the results to a significant extent.  
It is, due to lack of registration routines at the time, not known to what extent the Russian 
psychiatrists who took part are representative for all invited psychiatrists.  
7.8 Use of case simulation (paper II) 
Written case simulations (case vignettes) have been widely used to mimic a clinical situation 
in studies of medical decision-making, but their validity is not fully established. In psychiatry, 
case simulations have most often been used for testing of interrater reliability. Effect of 
gender in case simulations is not easy to find in existing literature, even if there are a few 
examples including this perspective - Stoppe et al (97) found that a female case vignette was 
diagnosed more often with (old age) depression in primary care than a male vignette, and 
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concluded, in line with our conclusions, that gender-related stereotypes and experiences 
affected the diagnosis.  
External validity of case simulations is most often discussed when “true” patients are 
compared with matching paper patients, as in an article by Borkhoff et al (98) on physician’s 
treatment and referral of total knee arthroplasty. In this study, gender was found to affect 
the clinicians’ decision when presented with a real patient but not so when presented a 
paper patient. This may imply case simulations to be less sensitive to gender differences –
hence; underline the strength of our findings. The results of the study also depend on the 
quality of the presented case – whether it gives a valid description of a patient where there 
is reasonable room for doubt. In our opinion, the results indicate that the description was 
quite accurate – schizophrenia diagnosis was given in about 70 % of the cases. The 
generalizability and hence the external validity of the results is enhanced by the fact that 
they are found both in the Russian and in the Norwegian cohort. 
8. General discussion - results 
The debate on the schizophrenia concept should lead to an open-mindedness towards 
investigating the boundaries of the syndrome (26, 34) in all senses  – gender differences as 
well as clinical practice, from different angles. The general results in the three studies 
presented in this thesis strongly support findings in other studies of an existing gender 
difference in symptomatology, both when it comes to clinicians’ interpretation and to 
outcome (mortality). None of the studies address to which degree men and women are 
actually treated differently. The discussion sections in each paper will not be repeated in 
this chapter, but a few general lines on the background of the different papers will be 
drawn.  
8.1 Latency period of schizophrenia diagnosis 
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The mean period from the first admission to first diagnosis of schizophrenia was 2.0 years 
overall (Paper I), but the latency period was significantly longer for females than for males.  
A similar gender difference has been found by others (99, 100). Goldacre et al (101) 
confirmed that when a diagnosis of schizophrenia has been made, it is less likely to be made 
at the patient’s first admission in females than in males. Chen et al (102) did not study 
latency period per se, but found that males have a higher rate of change from other 
disorders to schizophrenia than females, whereas females were more likely to have a 
change in diagnosis from schizophrenia to another disorder. The opposite seems to be the 
case in our study, but the methods used are different and may not be compared directly. 
As described in paper I, Kreitman el (103) outline five elements that characterize the 
diagnostic process: 1) the patient, 2) the psychiatric interview, 3) the psychiatrist, 4) the 
analysis and 5) the diagnosis. The focus of the study was the last three elements, which is 
reflected in the discussion in the paper.   
Our study is descriptive, and there are obvious limitations in interpretation of the results 
when patient issues are not included. The study was performed some years ago, and in light 
of current research the findings could very well be explained by gender-linked differences in 
symptomatology, as described in the Background chapter of the thesis (3.6 Sex and gender 
differences in schizophrenia) - independent of whether these differences are a result of 
neurodevelopmental, biological or general gender factors. 
In a study of stability of research diagnoses in a heterogeneous first-admission sample of 
patients with psychosis, Schwartz et al (104), used DSM IV diagnostic criteria at baseline and 
after 6 and 24 months. The most important risk factors for changing into schizophrenia 
diagnosis at 24 months follow-up were more than 3 months of psychosis duration before 
hospitalization, poorer premorbid adjustment in adolescence, having a longer length of 
hospitalization, being given antipsychotic medication upon hospital discharge, and having 
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more negative symptoms at 6-months follow-up. Schwartz et al thereby conclude that 
changes to schizophrenia diagnosis are mostly attributable to the evolution of the illness. 
Gender differences are not the issue in Schwartz et al’s paper, but as both poorer premorbid 
adjustment in adolescence and more negative symptoms are associated with male gender, 
this could be important for the gender differences in our study. This view is probably 
strengthened by the results of Kim et al (38), who investigated diagnostic stability in a group 
of first-episode psychotic patients. They found schizophrenia diagnosis to be the most 
consistent, but the rates of change to affective psychosis was significantly higher for 
women, as well as for patients with better premorbid functioning and shorter duration of 
untreated psychosis. This may indicate a higher degree of diagnostic uncertainty for women, 
and that clinical features evolve over some time in the beginning of the disease course. 
It has long been recognized that the onset of psychosis is often preceded with symptoms by 
a period of variable duration, and the pathways to any disorder or diagnosis is 
heterogeneous (34, 105). An important patient factor that has been emphasized since the 
mid-1990s is the duration of untreated psychosis (DUP). In a review by Nordentoft et al 
(106) the average duration of untreated psychosis is said to be around 1-2 years, and as 
several studies have linked longer duration of untreated psychosis with poorer outcomes 
this is of course an important research area.  
The duration of untreated psychosis (DUP) is not known in our study, but the current 
knowledge on gender differences in first-episode psychosis is obviously of importance in 
partly explaining our findings. Gender differences extend to pre-illness characteristics, as 
described by Cotton et al (107). They found that prior to onset of psychosis, women were 
more likely to have a history of suicide attempts and depressive symptoms, while men had 
more marked substance use problems, more severe psychopathology at admission and 
lower levels of social functioning. As for men; several studies also report more negative 
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symptoms (108 -110) and substance use (110, 111).  Substance abuse in relation to 
admission could mask the underlying symptoms and thereby prolong the diagnostic delay. 
In our study (Paper I), there were no significant difference between men and women in 
percentage distribution of alcohol- and drug-related disorder diagnoses, but the actual use 
of drugs and/or alcohol in relation to admissions is probably often not reflected in a 
diagnosis and hence underestimated.  
As gender and illness onset is complex also when it comes to first-episode psychosis (that is; 
also psychoses that might develop into schizophrenia), the patient history before and during 
first hospital admission could add important information. The patients in the case register 
may be in different stages in their disease course – some of them have had long duration of 
untreated psychosis before admission, and some may be admitted quite early in the course. 
In addition to the gender differences in symptomatology prior to schizophrenia diagnosis, it 
could be that the women are generally admitted in an earlier phase and therefore have a 
longer period of diagnostic uncertainty in-hospital. Both Larsen et al (112) and Thorup et al 
(110) found a longer duration of untreated psychosis in men, this could mean that the men 
in our study have been psychotic for a longer period, hence; the diagnosis could be more 
obvious. O’Callaghan et al (113) also concluded that being female, having better premorbid 
adjustment and fewer negative symptoms were associated with shorter delays in help-
seeking behaviour. 
 Still, the fact that the mean total period of observation inside hospital before first 
schizophrenia diagnosis was significantly longer for females than for males, indicate that the 
symptoms were serious also in women. The presumed serious symptoms may reflect that 
more women are either treated as outpatients or not treated at all before hospital 
admission. In addition to diagnostic uncertainty and gender-dependent aspects of disease 
course, the long observation period after admission may also be caused by poor treatment 
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response. We do, however, know nothing of the quality of symptoms or treatment given 
before or after admission, which is of course an obvious weakness of the study when it 
comes to the patient factor of the diagnostic process.  
Nevertheless; the focus of the study was the last three issues in Kreitman et al’s description 
– the psychiatrist, the analysis and the diagnosis. As an additional explanation could be that 
there is a systematically biased interpretation of symptoms by clinicians, for instance by not 
recognizing psychotic symptoms in women, a study of the diagnostic practice by clinicians 
was performed. Results shown in paper II confirm this assumption – to some degree a 
patient-independent gender bias may contribute to diagnostic delay.  
8.2 Clinicians’ former experience 
When considering differential diagnoses of a patient, the clinician must create a 
manageable list of relevant diagnoses, and manage to rule-out or rule-in differential 
diagnoses on the basis of former experience, observation and tests (114). With the 
experimental design of the second study (paper II), the gender differences have to be 
explained by the clinicians’ former experience, linked to earlier contact with patients and/or 










Clinicians may have observed more men than women with schizophrenia symptoms, and 
symptoms may have been more severe and more “typical” of schizophrenia at first 
presentation. Patient gender may thereby influence clinician’s decision-making concerning 
diagnosis at a later stage, as clinicians, more or less consciously, will include their former 
knowledge and experience concerning prognosis and aetiology when making diagnoses. 
Women’s higher degree of affective symptoms may, hypothetically, contribute to a better 
ability to verbalize and explain feelings. This can hypothetically make it easier for the 
clinician to understand and interpret symptoms as non-pathological reactions to stress and 
life events or as linked to the patient’s personality, and make it more difficult to choose the 
serious, more ‘‘organic’’ diagnosis of schizophrenia. As described by Cotton et al (107), 
women with first-episode psychosis also have a higher degree of traumatic experiences, 
suicide attempts and depressive episodes. Such experiences could, if expressed by the 
patient, contribute to this hypothesis.  However, this could only be an indirect explanation 
of the case simulation diagnosis. 
Gender differences in interpretation of symptoms are also known from other areas of 
medicine, as in acute heart disease (115). In a Norwegian study of diagnostic practice in a 
Pakistani versus a Norwegian population, Steihaug and Rutle (116) found that difference 
between the sexes was more significant than difference between Pakistani and Norwegian 
patients— women received more symptom diagnoses and fewer illness diagnoses than 
men. In the study by Borkhoff et al (98) mentioned in chapter 7.8 Use of case simulation, 
gender affected clinicians’ decisions; they were more likely to recommend total knee 
arthroplasty to men than to women with similar symptoms.  
Others have advocated the idea that psychiatry represents a value-laden cultural enterprise, 
and that diagnostic practice may suffer from so-called ‘‘androcentric bias’’ (male values and 
male behaviours are considered healthier and more normal). Physicians may thereby 
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overlook organic disease in women and consider their symptoms to be due to stress, life 
events or psychosexual problems. Seeman discusses this view in her book ‘‘Gender and 
psychopathology’’ (3), but emphasizes that the evidence for this view is ambiguous. 
8.3 Mortality and diagnostic practice 
Discussion of gender differences in mortality in paper III may be deepened by the results on 
diagnostic practice. The possible effect of treatment bias in paper III is described in 7. 
General discussion - methodology, included the possibility of a higher degree of serious 
symptoms in female patients in the latter period due to better treatment possibilities and 
decentralization of services.  In Paper I is shown that the latency period decreased gradually 
after introduction of new guidelines in 1987; this may counteract a possible bias, because of 
the broadened conceptualization of schizophrenia. 
Moreover, schizophrenia is a severe diagnosis that in most cases will lead to a period of 
hospital treatment at some point. The long follow-up period of the register probably 
attenuates bias risk; the chances of a patient with psychotic symptoms not being admitted 
are reduced as time passes. The longer the follow-up, the higher is the chance of being 
included in the register, even if this will not fully apply to patients eligible for first admission 
during the latest years of the register follow-up period.  As mentioned, psychiatric health 
care in the area is exclusively public, with well-established structures for cooperation on 
admission and follow-up. In addition, all involuntary treatment must be initiated in a 
hospital according to Norwegian legislation. Patients from the area admitted in other parts 
of Norway or as Norwegian citizens abroad will also be transferred to their “home” hospital.  
A possible association between diagnostic practice and cardiovascular mortality may arise 
on the background of results described in an article by Tabenkin et al (117), where visits by 
male and female patients at primary care physicians were investigated. After controlling for 
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visit and patient characteristics, it was found that visits by women had a higher percent of 
time spent on physical examination, structuring the intervention, patient questions, 
screening and emotional counselling. Visits by men, on the other hand, involved a higher 
percent of time spent on procedures and health behaviour counselling. Hence, clinicians’ 
bias in treating men and women with schizophrenia differently could be enhanced when it 
comes to health behaviour counselling; which is important in prevention of somatic 
morbidity. Still, further research is required. 
In the epidemiological overview by MacGrath et al (40) no difference in SMR between males 
and females was identified. A somewhat puzzling finding in this review was that the 
difference in incidence between men and women was not reflected in difference in 
prevalence – this should have been seen, according to the authors, if men have an earlier 
age of onset and a worse disease course at earlier stages. The findings of higher SMRs in our 
and other studies can contribute in explaining this lack of difference in prevalence. 
8.4 Internal and external validity 
We consider the internal validity in the analyses performed from the case register (Papers I 
and III) to be acceptable. It may be affected by the possible treatment bias, but it is 
important to underline that these are studies of in-patients, as most of the studies we 
compare with also are. Nevertheless, there might still be a group of well-functioning 
patients being treated without hospital admissions, thereby the validity of the study as a 
study of all patients in schizophrenia in the two counties Troms and Finnmark can be 
affected.  
All the results, except for the results from the simulation study, are based on the case 
register of the Department of Psychiatry at the northern-most university hospital in the 
world. Some of the observations are based on relatively old data (paper I) and follow-up of 
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patients during a long follow-up, the latter being a necessity in a prospective study. 
However, we find that the results in many respects are well in accordance with other similar 
studies. Furthermore, we believe that the results (with some reservations) have external 
validity for patients with schizophrenia treated under similar, relatively well functional, 
mental health care systems like in the Nordic countries and some other European countries.  
Caution must of course be made in interpreting the results in terms of causality as the 
results from Paper I and Paper III are from observational epidemiological studies. 
9. Clinical implications 
1. Women may receive less specific treatment than males, or correct treatment may be 
given at a later point. Special care must be taken in observing and interpreting the 
symptoms of women. 
2. Clinicians’ gender bias should be taken into consideration in studies of diagnostic 
reliability, as well as in studies addressing gender differences in general.  
3. The increasing mortality of patients with schizophrenia should be taken very seriously in 
further planning of health services, as well as in clinical practice. Prevention of somatic 
diseases should be considered just as important as prevention of suicides in this group 
of patients.  
4. The indications of rising SMRs for women should warrant extra caution. There might be 
subgroups of relatively well functioning, but vulnerable women who need better follow-
up than given in the existing, deinstitutionalized health care system.   
10. Research implications 
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1. The presented study on mortality is based on a cohort from only two Norwegian 
counties. The person-identifiable Norwegian Patient Registry established from 2008 
contains national cohorts, but has existed too short to provide a sufficient follow-up 
period. Register based studies on mortality development for patients with 
schizophrenia in general, and gender differences in particular, should be planned. 
2. As there is a delay in giving women schizophrenia diagnosis, but we have no 
information on the treatment given in this latency period, a closer investigation of 
treatment given to patients with first admission and psychosis diagnosis would be of 
interest.  
3. As our findings suggest that there may be a subgroup of vulnerable women with 
higher mortality, studies of gender differences in treatment before hospital 
admission and follow-up after hospital discharge should be performed. 
4. Closer investigation of gender-related stereotypes and the effect of former gender 
experiences among clinicians are subjects of interest, as it would be useful to create 
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Case description 
 
Background for admission 
A 27-year-old woman, who during the last 4–5 weeks has isolated herself and has suffered 
from increasing mental symptoms. The last 2 weeks she has stayed away from her job as a 
salesperson, without giving any reason. She has isolated herself at home, her colleagues and 
parents have tried to contact her by phone several times without success. The day before 
admission to hospital she came to her parents’ house at 4 o’clock in the morning, at that 
point she seemed anxious and suspicious. She spoke quite incoherently, saying that ‘‘things 
are connected’’, that she was ‘‘being disturbed all the time’’ and that two named, earlier 
class mates ‘‘don’t leave me alone’’. She also talked about reincarnation and her relationship 
to religious matters, and accused her parents for not being open-minded. She told them she 
had not been sleeping for a long time, and that she was afraid that ‘‘something terrible will 
happen’’. Her parents took her to the GP, who recommended admission to psychiatric 
hospital. The patient wanted herself to be admitted. 
 
Family/social factors 
She is the youngest of three siblings. Her parents are married, they say there have been 
numerous conflicts at home. Mother’s sister was once admitted to psychiatric hospital for a 
longer period, supposedly with a diagnosis of paranoid psychosis. Apart from this there has 
been no known psychiatric disease in the family. The patient lives in a small flat in her 
uncle’s house. The patient was shy in her childhood. She had some friends, and managed OK 
at school. During adolescence she stuck to herself, spent a lot of time with computers and 
music. She did not quite find her place among her friends, whom she claimed had other 
interests than herself. She could sometimes be quite rejecting if they tried to contact her, 
and her parents say she could be looked upon as a bit peculiar. She had one close friend she 
spent a lot of time with, but the contact was broken when the friend moved away. The 
patient finished high school with average grades. She went 9 months to a folk high school, 
but quit because she did not like it very much. She thereafter tried to study history of 
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religions at the University, but finished before her exam. Thereafter she has been 
unemployed, apart from several minor jobs in shops. 
She had a 1-year relationship to a boy the same age as her when she was 20; he finished the 
relationship. After that she has had little contact with boys. The last couple of years she has 
been interested in Buddhist religion and culture, and she is in contact with some people with 
similar interests on the Internet. This interest has lead to conflicts with her parents, who 
think religious matters occupy her thoughts too much. She has some contact with friends 
from school, but otherwise she sticks a lot to herself.  
 
Earlier contact with psychiatric care  
She has not been admitted to hospital before. After the break with her boyfriend she had 
some contact with an outpatient clinic, but quit on her own initiative. After the break she 
experienced similar symptoms as now; the name of her boyfriend was repeated 
continuously and she had a clear imagination of his face in front of her. The symptoms 
disappeared after 2–3 weeks. Her GP has been in contact with her twice earlier, both times 
she has complained about diffuse muscular pain and sleeping problems. Apart from this she 
has had no other contact with health services. 
 
Psychiatric present state  
A 27-year-old woman, slightly strange clothing. She knows time and place. Good formal, 
reduced emotional contact. She answers questions, but stares at the floor and plucks her 
clothes. Normal to slightly lowered mood, slightly reduced mimic. Good impulse control. She 
confirms that the names of two classmates are constantly repeated in her head, she 
describes it as if her thoughts are ‘‘stuck’’. She is not able to sleep, and she gets ‘‘too many 
hostile thoughts’’ of these persons. She has no plans of hurting them in any way, but is afraid 
of her own feelings. She denies hearing voices, says it is her own thoughts she is hearing. She 
also denies that these persons are able to influence her directly in any way. Her symptoms 
started gradually after she met them on the street 6 weeks ago, and they did not say hello to 
her. She has also been thinking a lot about experiences from childhood, and she wonders 
whether these persons rejected her because she has done something terrible in a former life 
and that everything is connected in some way. She says she’s almost experiencing that ‘‘all 
the pieces fit’’, and that everything is becoming ‘‘a whole’’, but she ‘‘misses it just before it’s 
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completed’’. She clamps her hands to her head, explaining that it is difficult to concentrate. 
She tells that she believes fully in reincarnation, that she is trying to live her life as correctly 
as possible so that her next life will be better than this one. She claims that she for a long 
time has been planning to go to India, because she by doing so will come ‘‘home’’ and be 
accepted as she is. She finds her strong, repeated thoughts distressing, and they make her 
anxious. When asked about visual hallucinations, she says that she for several years has 
been able to see a ‘‘glowing aura’’ around persons with personal strength, and she claims 
this is an ability she has developed through several years. She communicates a strong 
interest in religious subjects, but she does not have well defined, religious delusions. 
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